Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

34733 reported adverse events

Drugs of this class: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE EMTRICITABINE BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE AND TENOFOVIR ALAFENAMIDE EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE TRUVADA

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 PAIN 2820
1 ANXIETY 2722
2 EMOTIONAL DISTRESS 2507
3 ECONOMIC PROBLEM 2490
4 ANHEDONIA 2311
5 FOETAL EXPOSURE DURING PREGNANCY 1365
6 DRUG INTERACTION 1250
7 NAUSEA 1234
8 DIARRHOEA 1218
9 FATIGUE 1101
See all common reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CLOACAL EXSTROPHY 24 0.5581
1 ACUTE HIV INFECTION 80 0.5479
2 HIV VIRAEMIA 16 0.5333
3 FEAR-RELATED AVOIDANCE OF ACTIVITIES 31 0.5000
4 SPINOCEREBELLAR DISORDER 17 0.4474
5 BLOOD HIV RNA 14 0.4000
6 BLADDER AGENESIS 25 0.3906
7 HYPERANDROGENISM 21 0.3500
8 CSF VIRUS IDENTIFIED 21 0.3387
9 BLOOD HIV RNA INCREASED 243 0.3356
See all enriched reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]